{
  "thread": {
    "uuid": "f7ac40e68562cf0c40ab7d3431e3cfd6db518ede",
    "url": "https://www.defenseworld.net/2025/08/14/zacks-research-expects-lower-earnings-for-quest-diagnostics.html",
    "site_full": "www.defenseworld.net",
    "site": "defenseworld.net",
    "site_section": "https://www.defenseworld.net",
    "site_categories": [
      "media"
    ],
    "section_title": "Defense World",
    "site_title": "Defense World",
    "title": "Zacks Research Expects Lower Earnings for Quest Diagnostics",
    "title_full": "Zacks Research Expects Lower Earnings for Quest Diagnostics",
    "published": "2025-08-14T08:25:00.000+03:00",
    "replies_count": 0,
    "participants_count": 1,
    "site_type": "news",
    "country": "US",
    "main_image": "",
    "performance_score": 0,
    "domain_rank": 38342,
    "domain_rank_updated": "2025-06-03T00:00:00.000+03:00",
    "licensing_agency": [],
    "social": {
      "facebook": {
        "likes": 0,
        "comments": 0,
        "shares": 0
      },
      "vk": {
        "shares": 0
      }
    }
  },
  "uuid": "f7ac40e68562cf0c40ab7d3431e3cfd6db518ede",
  "url": "https://www.defenseworld.net/2025/08/14/zacks-research-expects-lower-earnings-for-quest-diagnostics.html",
  "ord_in_thread": 0,
  "author": "Defense World Staff",
  "published": "2025-08-14T08:25:00.000+03:00",
  "title": "Zacks Research Expects Lower Earnings for Quest Diagnostics",
  "text": "Quest Diagnostics Incorporated ( NYSE:DGX – Free Report ) – Equities researchers at Zacks Research reduced their Q3 2025 earnings per share estimates for shares of Quest Diagnostics in a research note issued on Tuesday, August 12th. Zacks Research analyst R. Department now expects that the medical research company will earn $2.49 per share for the quarter, down from their prior forecast of $2.50. The consensus estimate for Quest Diagnostics’ current full-year earnings is $9.70 per share. Zacks Research also issued estimates for Quest Diagnostics’ Q4 2025 earnings at $2.41 EPS, FY2025 earnings at $9.73 EPS, Q1 2026 earnings at $2.27 EPS, Q2 2026 earnings at $2.72 EPS, Q3 2026 earnings at $2.57 EPS, Q4 2026 earnings at $2.53 EPS, FY2026 earnings at $10.09 EPS, Q1 2027 earnings at $2.54 EPS, Q2 2027 earnings at $2.77 EPS and FY2027 earnings at $10.85 EPS. Quest Diagnostics ( NYSE:DGX – Get Free Report ) last issued its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.62 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.05. Quest Diagnostics had a return on equity of 15.24% and a net margin of 9.01%. The firm had revenue of $2.76 billion for the quarter, compared to analyst estimates of $2.73 billion. During the same period in the prior year, the firm posted $2.35 EPS. The company’s revenue for the quarter was up 15.2% on a year-over-year basis. Several other analysts have also issued reports on DGX. Barclays increased their target price on Quest Diagnostics from $175.00 to $185.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 23rd. Robert W. Baird increased their target price on Quest Diagnostics from $191.00 to $194.00 and gave the stock an “outperform” rating in a report on Wednesday, April 23rd. JPMorgan Chase & Co. increased their target price on Quest Diagnostics from $180.00 to $190.00 and gave the stock a “neutral” rating in a report on Tuesday, May 6th. Wall Street Zen lowered Quest Diagnostics from a “buy” rating to a “hold” rating in a report on Sunday. Finally, UBS Group reduced their target price on Quest Diagnostics from $176.00 to $175.00 and set a “neutral” rating on the stock in a report on Friday, July 18th. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $186.00. Check Out Our Latest Analysis on Quest Diagnostics Shares of NYSE DGX opened at $178.98 on Wednesday. The firm has a market cap of $20.01 billion, a price-to-earnings ratio of 21.43, a P/E/G ratio of 2.37 and a beta of 0.46. Quest Diagnostics has a one year low of $146.17 and a one year high of $182.38. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.09 and a quick ratio of 0.99. The stock’s fifty day moving average price is $174.48 and its two-hundred day moving average price is $171.45. The company also recently announced a quarterly dividend, which will be paid on Monday, October 20th. Shareholders of record on Friday, October 3rd will be given a $0.80 dividend. This represents a $3.20 annualized dividend and a yield of 1.8%. Quest Diagnostics’s dividend payout ratio is presently 38.32%. In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 8,269 shares of the stock in a transaction dated Wednesday, July 30th. The stock was sold at an average price of $167.40, for a total value of $1,384,230.60. Following the completion of the transaction, the senior vice president directly owned 10,660 shares in the company, valued at approximately $1,784,484. This trade represents a 43.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link . Also, SVP Patrick Plewman sold 5,535 shares of the stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $175.00, for a total value of $968,625.00. Following the completion of the transaction, the senior vice president owned 19,219 shares of the company’s stock, valued at $3,363,325. This represents a 22.36% decrease in their ownership of the stock. The disclosure for this sale can be found here . Insiders sold 16,014 shares of company stock valued at $2,728,556 over the last quarter. Corporate insiders own 8.16% of the company’s stock. Several large investors have recently bought and sold shares of DGX. Pinnacle Bancorp Inc. raised its position in shares of Quest Diagnostics by 126.9% during the second quarter. Pinnacle Bancorp Inc. now owns 152 shares of the medical research company’s stock worth $27,000 after acquiring an additional 85 shares during the last quarter. MTM Investment Management LLC bought a new position in shares of Quest Diagnostics during the second quarter worth about $29,000. Bruce G. Allen Investments LLC raised its position in shares of Quest Diagnostics by 57.8% during the first quarter. Bruce G. Allen Investments LLC now owns 183 shares of the medical research company’s stock worth $31,000 after acquiring an additional 67 shares during the last quarter. First Horizon Advisors Inc. raised its position in shares of Quest Diagnostics by 76.6% during the first quarter. First Horizon Advisors Inc. now owns 189 shares of the medical research company’s stock worth $32,000 after acquiring an additional 82 shares during the last quarter. Finally, Golden State Wealth Management LLC raised its position in shares of Quest Diagnostics by 157.3% during the first quarter. Golden State Wealth Management LLC now owns 193 shares of the medical research company’s stock worth $33,000 after acquiring an additional 118 shares during the last quarter. 88.06% of the stock is currently owned by institutional investors. ( Get Free Report )Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.",
  "highlightText": "",
  "highlightTitle": "",
  "highlightThreadTitle": "",
  "language": "english",
  "sentiment": "negative",
  "categories": [
    "Economy, Business and Finance",
    "Health",
    "Science and Technology"
  ],
  "topics": [
    "Economy, Business and Finance->financial service",
    "Economy, Business and Finance->business reporting and performance",
    "Science and Technology->scientific research",
    "Science and Technology->economics"
  ],
  "ai_allow": true,
  "has_canonical": false,
  "breaking": false,
  "webz_reporter": false,
  "external_links": [
    "https://www.marketbeat.com/stocks/NYSE/DGX/",
    "https://www.marketbeat.com/stocks/NYSE/DGX/earnings/",
    "https://www.marketbeat.com/arnreports/ReportTickerOptin.aspx?RegistrationCode=TickerHyperlink&Prefix=NYSE&Symbol=DGX",
    "https://www.insidertrades.com/quest-diagnostics-incorporated-stock/karthik-kuppusamy/",
    "http://www.sec.gov/Archives/edgar/data/1022079/000102207925000195/xslF345X05/wk-form4_1754080639.xml",
    "http://www.sec.gov/Archives/edgar/data/1022079/000149736825000005/xslF345X05/wk-form4_1754685636.xml",
    "https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=DGX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat",
    "https://marketbeat.com/stocks/NYSE/DGX/",
    "https://marketbeat.com/stocks/NYSE/DGX/earnings/",
    "https://insidertrades.com/quest-diagnostics-incorporated-stock/karthik-kuppusamy/",
    "https://www.wallstreetzen.com/newsletters/zen-ratings",
    "https://www.marketbeat.com/arnreports/ReportTickerOptin.aspx",
    "https://marketbeat.com/arnreports/ReportTickerOptin.aspx?RegistrationCode=TickerHyperlink&Prefix=NYSE&Symbol=DGX",
    "http://sec.gov/Archives/edgar/data/1022079/000102207925000195/xslF345X05/wk-form4_1754080639.xml",
    "https://wallstreetzen.com/newsletters/zen-ratings?ticker=DGX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat",
    "https://www.marketbeat.com/stocks/NYSE/DGX/earnings",
    "http://sec.gov/Archives/edgar/data/1022079/000149736825000005/xslF345X05/wk-form4_1754685636.xml",
    "https://www.insidertrades.com/quest-diagnostics-incorporated-stock/karthik-kuppusamy",
    "https://www.marketbeat.com/stocks/NYSE/DGX"
  ],
  "external_images": [],
  "internal_images": [],
  "entities": {
    "persons": [],
    "locations": [],
    "organizations": [
      {
        "name": "Zacks Research",
        "sentiment": "negative",
        "tickers": [
          {
            "ticker": null,
            "exchange": null
          }
        ]
      },
      {
        "name": "Quest Diagnostics Incorporated",
        "sentiment": "negative",
        "tickers": []
      }
    ]
  },
  "syndication": {
    "syndicated": false,
    "syndicate_id": null,
    "first_syndicated": false
  },
  "trust": {
    "categories": [],
    "top_news": [],
    "bias": null,
    "source": {
      "type": null,
      "city": null,
      "state": null,
      "country": null,
      "domain_type": null,
      "agency": null,
      "organization_name": null
    }
  },
  "rating": null,
  "crawled": "2025-08-14T08:42:44.348+03:00",
  "updated": "2025-08-14T08:53:58.000+03:00"
}